Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromesElsa Bernard, Alexandra Smith, Araxe Sarian et al.|Nature Medicine|2020Cited by 633
Prognostic Score Including Gene Mutations in Chronic Myelomonocytic LeukemiaRaphaël Itzykson, Éric Solary, Olivier Kosmider et al.|Journal of Clinical Oncology|2013Cited by 543
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemiasRaphaël Itzykson, Olivier Kosmider, Thomas Cluzeau et al.|Leukemia|2011Cited by 464
Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemiaLise Willems, Didier Bouscary, Nathalie Jacque et al.|Blood|2013Cited by 286
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)Olivier Kosmider, Véronique Gelsi‐Boyer, Meyling Cheok et al.|Blood|2009Cited by 270